Table 4.

Effects of PX-866 on glucose tolerance in mice

TreatmentAUC0-180 min (mg min mL-1)AUC0-180 min (mg min mL-1)
A. PX-866 10 mg/kg orally
No drug369 ± 25533 ± 17*
Insulin 0.075 μ/kg i.p.64 ± 25*64 ± 5
Metformin 250 mg/kg i.p. QD × 5367 ± 46537 ± 4
Pioglitazone 10 mg/kg i.p. QD × 7274 ± 3*340 ± 39
B. PX-866 3 mg/kg orally QOD × 20
520 ± 14*
8-d recovery343 ± 30
Pioglitazone 10 mg/kg i.p.405 ± 26§
QD × 7
  • NOTE: Female C57Bl/6 mice were fasted overnight and given d(+)-glucose 1 mg/kg as a 0.1 g/mL solution orally. Blood was collected at various times up to 180 min and plasma glucose measured to obtain a plasma glucose area under the curve (AUC0-180 min). Mice were given PX-866 10 mg/kg orally and glucose given 4 h later, or PX-866 3 mg/kg orally every other day for 20 doses and glucose given 24 h or 8 d after the last dose. Metformin was given at 250 mg/kg daily for 5 d and pioglitazone at 10 mg/kg i.p. daily for 7 d before glucose administration. Human recombinant insulin was given at 0.075 μ/kg i.p. at the same time as glucose. Values are the mean ± SE of four mice per group.

  • * P < 0.05 compared with untreated control.

  • P < 0.05 compared with drug-treated control without PX-866.

  • P < 0.05 compared with PX-866 alone.

  • § P < 0.05 compared with chronic PX-866 alone.